natgillin/translations-raw huggingface dataset:
Within the studied regimens of daclizumab 150 mg and 300 mg administered subcutaneous every 4 weeks in MS patients, there was no clear relationship between daclizumab exposure and clinical efficacy endpoints (ARR, T2 lesions and Gd-enhancing lesions) or safety endpoints of interest (serious infection status, moderate or severe cutaneous adverse reaction, and AST/ALT &gt; 5 times the ULN).
Unutar ispitivanih režima daklizumaba od 150 mg i 300 mg primijenjenih supkutano svaka 4 tjedna u bolesnika s MS-om, nije bilo jasnog odnosa između izloženosti daklizumabu i ishoda kliničke djelotvornosti (godišnje stope relapsa, lezije na T2-mjerenoj snimci i lezije imbibirane gadolinijem) ili ishoda sigurnosti od interesa (stanje ozbiljne infekcije, umjerene ili teške kožne nuspojave, i AST/ALT &gt; 5 puta GGN).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
U klasifikaciji prema organskim sustavima, nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje nuspojava), uz uporabu sljedećih kategorija: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100, &lt; 1/10); uncommon (≥ 1/1,000, &lt; 1/100); rare (≥ 1/10,000, &lt; 1/1,000); very rare ( &lt; 1/10,000).
U klasifikaciji prema organskim sustavima, nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje nuspojava), uz uporabu sljedećih kategorija: vrlo često (≥ 1/10); često (≥ 1/100, do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su poredane prema učestalosti (broj bolesnika kod kojih se očekuje pojava nuspojava), koristeći sljedeće kategorije: vrlo često: (≥1/10); često: (≥1/100 do &lt; 1/10); manje često: (≥1/1000 do &lt; 1/100); rijetko: (≥1/10 000 do &lt; 1/1000); vrlo rijetko: ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su poredane prema učestalosti (broj bolesnika kod kojih se očekuje pojava nuspojava), koristeći sljedeće kategorije: vrlo često: (≥1/10); često: (≥1/100 do &lt; 1/10); manje često: (≥1/1000 do &lt; 1/100); rijetko: (≥1/10,000 do &lt; 1/1000); vrlo rijetko: ( &lt; 1/10,000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the system organ classes, adverse reactions are listed under headings of the following frequency categories: very common (≥1/10), common (≥1/100 to &lt; 1/10) and uncommon (≥1/1,000 to &lt; 1/100).
Unutar klasifikacije organskih sustava, nuspojave su navedene prema sljedećim kriterijima učestalosti: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10) i manje često (≥1/1000 do &lt; 1/100).
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Unutar klasa organskih sustava nuspojave su razvrstane prema sljedećim kategorijama učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti prema dostupnim podacima).
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Unutar pojedinog organskog sustava nuspojave su razvrstane prema sljedećim kategorijama učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti prema dostupnim podacima).
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (1/10); common (1/100 to &lt; 1/10); uncommon (1/1,000 to
Unutar pojedinog organskog sustava nuspojave su razvrstane prema sljedećim kategorijama učestalosti: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti prema dostupnim podacima).
Without affecting the primary endpoint, overall response rate (32% vs 25%, p = 0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p &lt; 0.01) and median survival (15.3 months vs 12.7 months; p = 0.03).
Bez utjecaja na primarni ishod, ukupnu stopu odgovora (32% prema 25%, p=0,10), docetaksel je produljio medijan vremena do progresije bolesti (24,6 tjedana prema 15,6 tjedana; p &lt; 0,01) i medijan vremena preživljenja (15,3 mjeseca prema 12,7 mjeseci; p=0,03).
Without affecting the primary endpoint, overall response rate (32% vs 25%, p=0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p &lt; 0.01) and median survival (15.3 months vs 12.7 months; p=0.03).
Bez utjecaja na primarni ishod, ukupnu stopu odgovora (32% prema 25%, p=0,10), docetaksel je produljio medijan vremena do progresije (24,6 tjedana prema 15,6 tjedana; p &lt; 0,01) i medijan vremena preživljenja (15,3 mjeseca prema 12,7 mjeseci; p=0,03).
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 &amp; 4.5).
U žena reproduktivne dobi oralni kontraceptivi ne smiju se primjenjivati kao jedina metoda kontrole začeća jer nevirapin može sniziti koncentracije tih lijekova u plazmi (vidjeti dijelove 4.4 i 4.5).
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 &amp; 4.5).
U žena reproduktivne dobi oralni kontraceptivi ne smiju se primjenjivati kao jedina metoda kontrole začeća jer nevirapin može sniziti koncentracije tih lijekova u plazmi (vidjeti dijelove 4.4. i 4.5.).
Women, the elderly, patients with low body weight or with moderate renal impairment (creatinine clearance &gt; 30 - &lt; 50 ml/min) may have an increased risk of bleeding.
Žene, stariji, osobe male tjelesne težine ili s umjerenim oštećenjem bubrega (klirens kreatinina  30 do ≤ 50 ml/min) mogu imati povećani rizik od krvarenja.
Worst-case QTc prolongation of &gt; 60 millisecond (msec) was observed in 3% of dabrafenib-treated subjects (one &gt; 500 msec in the integrated safety population).
Najteži slučaj produljenja QTc od &gt; 60 milisekundi (ms) zabilježen je u 3% ispitanika liječenih dabrafenibom (jedan &gt; 500 ms u integriranoj sigurnosnoj populaciji).
Wound halves treated with Episalvan healed faster than the wound halves treated with standard of care (mean 1.1 days according to primary endpoints, p &lt; 0.0001, two-sided paired t-test).
Polovice rana liječenih Episalvanom zacijelile su brže nego polovice rana liječenih standardnim postupcima (prosječno 1,1 dan prema primarnim ishodima, p &lt; 0,0001, dvostrani upareni t-test).
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 135) Median 7.4 months; Placebo -------- (N = 67) Median 4.2 months; Hazard Ratio = 0.54, 95 % CI (0.35, 0.84), P &lt; 0.001
os x; mjeseci, os y; udio bez progresije, pazopanib —―— (N = 135) medijan 7,4 mjeseca; placebo -------- (N = 67) medijan 4,2 mjeseca; omjer hazarda = 0,54; 95% CI (0,35; 0,84), P &lt; 0,001
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 155) Median 11.1 months; Placebo -------- (N = 78) Median 2.8 months; Hazard Ratio = 0.40, 95 % CI (0.27, 0.60), P &lt; 0.0000001
Months os x; mjeseci, os y; udio bez progresije, pazopanib —―— (N = 155) medijan 11,1 mjeseci; placebo -------- (N = 78) medijan 2,8 mjeseci; omjer hazarda = 0,40; 95% CI (0,27; 0,60); P &lt; 0,0000001
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 290) Median 9.2 months; Placebo -------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95 % CI (0.34, 0.62), P &lt; 0.0000001
Months os x; mjeseci, os y; udio bez progresije, pazopanib —―— (N = 290) medijan 9,2 mjeseca; placebo -------- (N = 145) medijan 4,2 mjeseca; omjer hazarda = 0,46; 95% CI (0,34; 0,62); P &lt; 0,0000001
Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI &gt; 28 kg/m²) with associated risk factors.
Xenical je u kombinaciji s blago hipokalorijskom dijetom indiciran za liječenje pretilih bolesnika kojima je indeks tjelesne mase (BMI = Body Mass Index) 30 kg/m² ili veći, kao i u bolesnika s prekomjernom tjelesnom težinom (BMI ≥ 28 kg/m²) i pridruženim faktorima rizika.
Xeplion is not recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min) (see section 4.4).
Xeplion se ne preporučuje u bolesnika s umjerenim ili teškim bubrežnim oštećenjem (klirens kreatinina &lt; 50 ml/min) (vidjeti dio 4.4).
Xeplion is not recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min) (see sections 4.2 and 5.2).
Ne preporučuje se primjena lijeka Xeplion u bolesnika s umjerenim ili teškim oštećenjem bubrega (klirens kreatinina &lt; 50 ml/min) (vidjeti dijelove 4.2 i 5.2).
Xeristar must not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min; see section 4.3).
Xeristar se ne smije primjenjivati u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina &lt; 30 ml/min; vidjeti dio 4.3).
Xiliarx is not recommended for use in children and adolescents under ( &lt; 18 years).
Xiliarx se ne preporučuje za primjenu u djece i adolescenata ( &lt; 18 godina).
Xiliarx should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2).
Xiliarx se ne smije primjenjivati u bolesnika s oštećenjem jetre, uključujući bolesnike u kojih su vrijednosti alanin aminotransferaze (ALT) ili aspartat aminotransferaze (AST) prije početka liječenja bile &gt; 3x vrijednosti gornje granice normale (GGN) (vidjeti također dijelove 4.4 i 5.2).
Xiliarx should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST &gt; 3x ULN (see also sections 4.2 and 5.2).
Xiliarx se ne smije primjenjivati u bolesnika s oštećenjem funkcije jetre, uključujući bolesnike u kojih su ALT ili AST prije početka liječenja bili &gt; 3x vrijednosti GGN (vidjeti također dijelove 4.2 i 5.2).
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 &lt; 80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high- dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.
Xolair je indiciran kao dodatna terapija za poboljšanje kontrole astme u bolesnika s teškom perzistentnom alergijskom astmom koji imaju pozitivan kožni test ili in vitro reaktivnost na cjelogodišnji inhalacijski alergen te koji imaju smanjenu funkciju pluća (FEV1 &lt; 80%) kao i česte simptome tijekom dana ili buđenja tijekom noći i koji imaju višestruke dokumentirane teške egzacerbacije astme, usprkos visokim dnevnim dozama inhalacijskih kortikosteroida uz dugodjelujući inhalacijski beta2-agonist.
Xolair is indicated in adults, adolescents and children (6 to &lt; 12 years of age).
Xolair je indiciran u odraslih, adolescenata i djece (6 do &lt; 12 godina starosti).
Xoterna Breezhaler demonstrated a statistically superior improvement versus tiotropium in the percentage of “days able to perform usual daily activities” over 26 weeks (8.45%, p &lt; 0.001).
Xoterna Breezhaler pokazao je statistički značajno poboljšanje u odnosu na tiotropij u postotku „dana kada mogu obavljati uobičajene svakodnevne aktivnosti“ tijekom 26 tjedana (8,45%, p &lt; 0,001).
Xoterna Breezhaler increased post-dose FEV1 AUC0-12 (primary endpoint) by 140 ml at 26 weeks (p &lt; 0.001) compared to fluticasone/salmeterol.
Xoterna Breezhaler povećao je FEV1 AUC0-12 nakon doze (primarni ishod) za 140 ml u 26 tjedana (p &lt; 0,001) u usporedbi s flutikazonom/salmeterolom.
Xoterna Breezhaler increased post-dose trough FEV1 by 200 ml compared to placebo at the 26-week primary endpoint (p &lt; 0.001) and showed statistically significant increases compared to each monotherapy component treatment arm (indacaterol and glycopyrronium) as well as the tiotropium treatment arm, as shown in the below table.
Xoterna Breezhaler je povećao najniži FEV1 nakon doze za 200 ml u usporedbi s placebom u primarnom ishodu u 26 tjednu (p &lt; 0,001) i pokazao statistički značajno povećanje u usporedbi sa svakom terapijskom skupinom koja je primala monoterapiju jednom od komponenti (indakaterolom i glikopironijem), kao i u terapijskoj skupini koja je primala tiotropij, kako je prikazano u tablici u nastavku.
Year 1 and 3 frequencies of malignancies are shown in Table 3, except for cases of PTLD which are presented at 1 year and &gt; 3 years (median days of follow-up were 1,199 days for belatacept MI, 1,206 days for belatacept LI, and 1,139 days for ciclosporin).
Učestalost zloćudnih bolesti u 1. i 3. godini prikazana je u tablici 3, osim slučajeva PTLD koji su prikazani nakon 1 godine i &gt; 3 godine (medijan dana praćenja iznosio je 1199 dana za belatacept MI, 1206 dana za belatacept LI i 1139 dana za ciklosporin).
YENTREVE must not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min; see section 4.3).
YENTREVE se ne smije primjenjivati u bolesnica s teškim oštećenjem bubrežne funkcije (klirens kreatinina &lt; 30 ml/min; vidjeti dio 4.3).
YES NO Does the patient have prolonged QT interval at baseline (uncorrected &gt; 440 msec)?
DA NE Ima li bolesnik produljen QT-interval na početku liječenja (nekorigirani &gt; 440 ms)?
Yondelis monotherapy and combination regimens must not be used in patients with creatinine clearance &lt; 30 ml/min and &lt; 60 ml/min respectively (see section 4.2).
Monoterapija Yondelisom i kombinirani režimi ne smiju se koristiti kod bolesnika koji imaju klirens kreatinina &lt; 30 ml/min, odnosno &lt; 60 ml/min (vidjeti dio 4.2).
you are unable to walk for a long time because of major surgery, injury or illness (see also section 3, if you need to have surgery) you are seriously overweight (BMI &gt; 30 kg/m2)
ne možete hodati dulji period zbog veće operacije, ozljede ili bolesti (vidjeti također dio 3, ako trebate na operaciju) izrazito ste pretili (ITM &gt; 30 kg/m2)
Younger children (0 &lt; 6 years)
Mlađa djeca (0 &lt; 6 godina)
Younger children (0 &lt; 6 years)
Mala djeca (0 – &lt; 6 godina)
Your doctor may ask you to use a moisturiser, sun screen (SPF &gt; 15), topical steroid, and/or oral antibiotics which may help in the management of skin toxicities that can be associated with the use of Vectibix.
Vaš liječnik Vam može preporučiti upotrebu sredstava za ovlaživanje kože, zaštitu od sunca (SPF &gt; 15), površinski steroid i/ili oralni antibiotik, koji mogu biti od pomoći u liječenju kožnih toksičnosti koje mogu biti povezane s upotrebom lijeka Vectibix.
your kidneys do not work properly (creatinine clearance &lt; 30 ml/min) or if you are on dialysis as the use of this medicine is not recommended. you have moderate liver problems (hepatic impairment, Child Pugh B). you start or stop smoking during treatment with this medicine, because this may influence the level of riociguat in your blood.
Vaši bubrezi ne rade ispravno (klirens kreatinina &lt; 30 ml/min) ili ste na dijalizi, jer tada se ne preporučuje primjena ovog lijeka. imate umjerene tegobe s jetrom (oštećenje funkcije jetre, Child-Pugh B) počnete ili prestanete pušiti za vrijeme liječenja ovim lijekom, jer to može utjecati na razinu riocigvata u Vašoj krvi.
ZALTRAP should be suspended when proteinuria ≥2 grams per 24 hours and resumed when proteinuria &lt; 2 grams per 24 hours.
Primjenu lijeka ZALTRAP treba privremeno prekinuti kada je proteinurija ≥ 2 grama u 24 sata i nastaviti kada proteinurija bude &lt; 2 grama u 24 sata.
ZEPATIER for 16 weeks plus ribavirinA should be considered in patients with baseline HCV RNA level &gt; 800,000 IU/ml and/or the presence of specific NS5A polymorphisms causing at least a 5-fold reduction in activity of elbasvir to minimise the risk of treatment failure (see section 5.1).
Kako bi se minimizirao rizik od neuspjeha liječenja, treba se razmotriti 16-tjedno liječenje lijekom ZEPATIER plus ribavirinomA, u bolesnika s početnom razinom HCV RNK &gt; 800 000 IU/ml i/ili prisutnošću specifičnih polimorfizama u NS5A koji uzrokuju najmanje peterostruko smanjenje aktivnosti elbasvira (vidjeti dio 5.1).
ZEPATIER for 16 weeks plus ribavirinA should be considered in patients with baseline HCV RNA level &gt; 800,000 IU/ml to minimise the risk of treatment failure (see section 5.1).
Kako bi se minimizirao rizik od neuspjeha liječenja, treba se razmotriti 16-tjedno liječenje lijekom ZEPATIER plus ribavirinomA, u bolesnika s početnom razinom HCV RNK &gt; 800 000 IU/ml (vidjeti dio 5.1).
Ziconotide is a relatively small molecular weight peptide (MW = 2,639) and is filtered by the kidney glomerulus, but only minimal amounts of ziconotide ( &lt; 1%) are recovered in human urine following intravenous infusion.
Zikonotid je peptid relativno male molekularne težine (MW = 2639) i filtrira se u bubrežnom glomerulu ali samo minimalne količine zikonotida ( &lt; 1%) nađu se u urinu nakon intravenske infuzije.
Ziconotide is a relatively small molecular weight peptide (MW = 2,639) and is filtered by the kidney glomerulus, but only minimal amounts of ziconotide ( &lt; 1%) are recovered in human urine following intravenous infusion.
Zikonotid je peptid relativno male molekularne težine (MW = 2639) i filtrira se u bubrežnom glomerulu ali samo se minimalne količine zikonotida ( &lt; 1%) nađu u urinu nakon intravenske infuzije.
Zidovudine is contraindicated in patients with abnormally low neutrophil counts ( &lt; 0.75 x 109/l), or abnormally low haemoglobin levels ( &lt; 7.5 g/dl or 4.65 mmol/l).
Zidovudin je kontraindiciran u bolesnika s izrazito niskim brojem neutrofila ( &lt; 0,75 x 109/l), ili s izrazito niskom razinom hemoglobina ( &lt; 7,5 g/dl ili 4,65 mmol/l).
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za &gt; 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient – skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate.
Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku – stopu koštanog pobola.
Zoledronic acid Actavis is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min.
Zoledronatna kiselina Actavis se ne preporučuje u bolesnika koji prije početka liječenja imaju teško oštećenje funkcije bubrega, koje se u ove populacije definira kao CLcr &lt; 30 ml/min.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies &lt; 3 % of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama &lt; 3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama &lt; 3% primijenjene doze otkrilo se u fecesu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronatna kiselina ne inhibira ljudske P450 enzime in vitro, ne metabolizira se, a u ispitivanjima na životinjama &lt; 3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.